Mechanisms of Light Chain Injury along the Tubular Nephron

Paul W. Sanders

Division of Nephrology, Department of Medicine, Nephrology Research and Training Center, Center for Free Radical Biology and Department of Physiology and Biophysics, University of Alabama at Birmingham, Birmingham, Alabama; and Department of Veterans Affairs, Medical Center, Birmingham, Alabama

ABSTRACT

The tubular nephron is responsible for reabsorption and catabolism of filtered low molecular weight proteins that include Ig free light chains. In the setting of a plasma cell dyscrasia, significant amounts of free light chains, now monoclonal proteins, present to the tubular nephron for disposal. The result may be clinical renal dysfunction in the form of AKI, progressive CKD, and end-stage kidney disease. Here, I review the mechanisms involved in these processes that result in tubular injury, including proximal tubulopathy and cast nephropathy.


One hundred sixty-seven years ago, some of the best physicians in the world struggled to understand the disease causing excruciating pain in their patient. The physicians identified a unique protein in the patient’s urine and asked the prominent chemical pathologist, Henry Bence Jones, for assistance. Bence Jones was unable to determine accurately the nature of this urinary protein that now bears his name, but he correctly surmised that the presence in the urine of Bence Jones protein served as a biomarker associated with moliitis ossium, now known as multiple myeloma.1 More than a century later, Gerald Edelman, who received the Nobel Prize in physiology and medicine for elucidating the structure of antibody molecules, reported that Bence Jones proteins were Ig free light chains (FLCs) that appeared in the urine in the work by Edelman and Gally.2 In a subsequent account of the events (http://www.webofstories.com/play/15758), Edelman suggested that this discovery was the end of the story on Bence Jones proteins, but for nephrologists, the story was just beginning.

More recent efforts have shown that polyclonal FLCs are produced daily during normal lymphoid metabolism and appear in the serum in significant amounts. Kidney function is essential in clearing FLCs, because nephrectomy prolongs the plasma half-life of these low molecular weight proteins but does not affect the half-life of high molecular weight proteins such as IgG.3 FLCs, but not IgG, are readily filtered through the glomerulus and appear in the tubular lumen,4 but they are rapidly reabsorbed by the proximal tubular epithelium after binding to a heterodimeric receptor composed of megalin and cubilin.5–7 This system is saturable but very efficient; therefore, under normal conditions, the majority of FLCs is removed from the tubular fluid, and little appears in the urine.8 However, when a plasma cell dyscrasia develops, the production of FLCs, now predominantly monoclonal proteins, increases, and circulating FLC levels can approach 100,000 mg/L.9 As a consequence, proximal tubular reabsorption can become saturated, and FLCs appear in the lumen of the distal nephron and finally, the urine as Bence Jones protein. Depending on the structure of the FLC (Figure 1), several renal tubular lesions may ensue, and they are the subject of this review.

FANCONI SYNDROME

A classic and well recognized proximal tubular lesion associated with multiple myeloma is Fanconi syndrome. This rare disorder occurs when the FLC undergoes homotypic polymerization within the endolysosomal system of the proximal tubular epithelium to form intracellular crystals, which are the distinguishing pathologic characteristics of this syndrome. Clinical manifestations include the features of Fanconi syndrome (defects in sodium-coupled cotransport processes producing type II renal tubular acidosis, aminoaciduria, phosphaturia, and glycosuria). The associated multiple myeloma is often low-grade.10 The offending monoclonal FLCs are usually
in the κ1 subclass and possess unusual nonpolar or hydrophobic residues in complementarity-determining region1 (CDR1).11

In an interesting proof-of-concept experiment showing that the V\textsubscript{L} domain specifically produced this syndrome, the work by Sirac et al.12 generated a transgenic mouse in which the endogenous murine κ\textsubscript{c} cluster was replaced with a V\textsubscript{κ}κ\textsubscript{c} gene segment cloned from a patient who had myeloma-associated Fanconi syndrome. The work by Sirac et al.12 detailed observations of the appearance in the circulation of a chimeric FLC that consisted of the V\textsubscript{L} domain of human κ1 subclass and the murine C\textsubscript{L} domain. Importantly, this work12 also showed recapitulation of the clinical features of Fanconi syndrome and the pathologic changes observed in human proximal tubular cells, including crystal formation and proximal tubular epithelial cell injury. The renal lesion was reversed when the human V\textsubscript{κ} gene was deleted, suggesting that effective chemotherapy would benefit patients with this disorder.12

This unique proximal tubular lesion may represent a subset of gammopathy-associated crystal-storing histiocytosis, in which crystal-forming monoclonal Igs, composed of heavy chains and typically, κ-FLC, accumulate in lysosomes of histiocytes in soft tissues, kidney, bone marrow, spleen, liver, stomach, and other organs.13 Involvement of the proximal tubule occurs specifically when the monoclonal FLC is overproduced, because intact Ig is not filtered through the glomerulus.

**PROXIMAL TUBULOPATHY**

FLCs also promote cytotoxicity through mechanisms that are distinct from crystal formation. Perfusion in vivo of proximal convoluted tubules of rats with human monoclonal FLCs promotes functional and morphologic evidence of direct toxicity along with expansion of the endolysosomal system but only occasional intracellular crystal formation.14,15 Additional studies provided clinical correlation by showing similar morphologic features of isolated proximal tubular injury in patients who had myeloma but no evidence of intraluminal cast formation.16 Human monoclonal FLCs are readily endocytosed into proximal tubular cells in culture and are cytotoxic.7,17 FLCs may be directly toxic to proximal tubular cells by blocking glucose, amino acid, or phosphate transport.14,15,18–21 Recently, monoclonal FLCs, but not polyclonal FLCs, have been shown to generate intracellular oxidative stress, particularly in the form of hydrogen peroxide.22 Hydrogen peroxide promotes redox-signaling events that result in the production of chemokines and cytokines as well as apoptosis of the proximal tubular cells.21–23 These events seem to begin after endocytosis through the tandem endocytic receptors composed of cubilin and megalin.5–7,21,23

Redox-sensitive pathways that may be activated by monoclonal FLCs include NF-κB and mitogen-activated protein kinases. Activation of NF-κB is complicated and involves Src kinase, which activates both canonical and atypical NF-κB pathways.24 Proximal tubular cells exposed to monoclonal FLCs produce inflammatory and profibrotic molecules that include IL-6, monocyte chemotactic protein-1, IL-8, and TGF-β1.17,22,24,26–28 The anticipated outcome might include interstitial fibrosis and phenotypic transformation of proximal tubular cells into fibroblasts through epithelial–mesenchymal transition.17,28–31

Monoclonal FLC-mediated redox signaling also promotes apoptosis.25 In particular, monoclonal FLCs activate the mitogen-activated protein kinase kinase kinase known as apoptosis signal-regulating kinase 1 (ASK1). ASK1 is an important cellular redox sensor and key element in oxidative stress-induced apoptosis.32 ASK1 resides in the cytoplasm complexed to thioredoxin.33,34 When oxidized, thioredoxin releases ASK1, permitting phosphorylation and activation of this enzyme. ASK1 activates JNK and p38 mitogen-activated protein kinase pathways, resulting in cytochrome c release from mitochondria and activation of caspases 9 and finally, 3,35–38 Pretreatment of proximal tubular cells in culture with small interfering RNA reduced ASK1 expression and prevented monoclonal FLC-induced apoptosis. There seems to be a balance between apoptosis and NF-κB activation of proximal tubular cells; the mediator may be Src kinase, which promotes NF-κB activation,24 but it also directly phosphorylates and therefore, down-regulates ASK1 (Figure 2).25

The clinical effects on proximal tubule function seem to be significant. Apoptosis is a feature of experimental monoclonal FLC-induced renal failure in animals.30 An isolated proximal tubulopathy that promotes clinical manifestations of renal failure associated with monoclonal FLC-induced proximal tubular injury is much less common than...
cast nephropathy.\textsuperscript{14,39} However, the direct cellular effects of FLC may be important in cast nephropathy (discussed below) by not only promoting apoptosis but also generating an intrarenal inflammatory milieu that promotes the rapid tubulointerstitial fibrosis\textsuperscript{40} and progressive renal failure that is often observed after a bout of AKI in patients with multiple myeloma. As shown by the experimental work from the laboratory of Batuman that was published in the work by Ari

mura \textit{et al.},\textsuperscript{41} interventions designed to inhibit or counteract these redox-signaling pathways may, therefore, prove to be beneficial in myeloma kidney.

**CAST NEPHROPATHY**

The dominant tubulointerstitial lesion associated with multiple myeloma is cast nephropathy. The characteristic finding is the presence of multiple intraluminal proteinaceous casts. The casts are usually acellular, homogeneous, and eosinophilic with multiple fracture lines. An interesting giant cell inflammatory reaction develops if the casts persist. Tubular atrophy and interstitial inflammation accompany the casts, and some works suggest that the term—myeloma kidney—is, therefore, perhaps more appropriate than cast nephropathy. For the chronic progressive kidney disease, the potential involvement of the proximal tubule, along with cast formation, supports the use of this term. However, experimental evidence confirms that intraluminal cast formation is the proximate cause of AKI and likely, the initiation step in the subsequent progressive deterioration in renal function.

Intravenous infusion of monoclonal FLC in rats elevates proximal tubule pressure and simultaneously decreases single nephron GFR; intraluminal protein casts were identified in these kidneys.\textsuperscript{42} A series of studies shows that the myeloma casts contain Tamm–Horsfall glycoprotein (Figure 3) and occur initially in the distal nephron, which provides an optimum environment for coprecipitation with the monoclonal FLCs; these FLCs, in turn, bind to a specific site on Tamm–Horsfall glycoprotein through the CDR3.\textsuperscript{15,43–50}

Capitalizing on this latter observation, a recent study analyzed this interaction and showed that the secondary structure and key amino acid residues on the CDR3 of the FLCs were critically important determinants of the molecular interaction with Tamm–Horsfall glycoprotein. These findings permitted development of a strongly inhibiting cyclized competitor peptide. When used in a rodent model of cast nephropathy, this cyclized peptide construct inhibited cast formation and the associated functional manifestations of AKI \textit{in vivo}.\textsuperscript{50} These experiments critically show that intraluminal cast formation was integrally involved in the pathogenesis of AKI from cast nephropathy. Furthermore, the data support a clinically relevant and novel approach to the management of FLC-mediated AKI in the setting of multiple myeloma.\textsuperscript{50} Finally, the luminal environment can affect binding of the offending FLCs with Tamm–Horsfall glycoprotein. Therefore, in addition to
effective chemotherapy and other developing treatment strategies, clinical efforts to increase tubular fluid flow rates, such as increasing water intake, avoiding agents that alter intrarenal hemodynamics (non-steroidal anti-inflammatory agents), and limiting intraluminal sodium concentration through avoidance of diuretics when circulating FLCs are high, are additional interventions that may prevent progressive renal injury.

CONCLUSIONS

Although oncologists might focus on the M protein, nephrologists must determine renal risk to tubular function by assessing circulating monoclonal FLCs. In one large study of multiple myeloma, for example, renal failure was present in approximately 2% of patients who did not have significant urinary FLC levels. In contrast, increasing urinary FLC levels strongly associated with renal failure, with 48% of patients who had high urinary monoclonal FLCs also showing renal failure and associated poor survival.\(^1\) The advent of a nephelometric assay that quantifies serum FLCs represents a significant advance, because the filtered load of the monoclonal FLCs may be extrapolated to risk to renal failure, permitting earlier intervention in the management of these patients. A basic knowledge of the renal handling of proteins is key to understanding the pathomechanisms involved in FLC-mediated tubular injury and providing appropriate therapeutic interventions in the management of tubular injury in myeloma.

By uncovering the underlying renal tubular pathobiology and showing new therapeutic interventions, the field has progressed significantly since the initial observations of Henry Bence Jones, but additional work is needed before declaring an end to the story on Bence Jones proteins.

ACKNOWLEDGMENTS

The laboratory of P.W.S. is supported by National Institutes of Health Grants R01 DK046199 and P30 DK079337 (George M. O’Brien Kidney and Urological Research Centers Program) and the Office of Research and Development, Medical Research Service, Department of Veterans Affairs.

DISCLOSURES

None.

REFERENCES

27. Sengul S, Zwizinski C, Batuman V: Role of MAPK pathways in light chain-induced


